[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 330 4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 67, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 66, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 552017, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 52, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 40893, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 48, "title": "CFO, Head of Business Development, Principal Accounting Officer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 607383, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew  Winton Ph.D.", "age": 46, "title": "Senior VP & COO", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 602100, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Demetrios  Braddock M.D., Ph.D.", "title": "Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Senior VP, Chief Scientific Officer & Chair of the Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Di Palma M.B.A.", "age": 65, "title": "Consultant", "yearBorn": 1959, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Petra  Duda M.D., Ph.D.", "title": "Chief Medical Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.96, "open": 3.95, "dayLow": 3.95, "dayHigh": 3.96, "regularMarketPreviousClose": 3.96, "regularMarketOpen": 3.95, "regularMarketDayLow": 3.95, "regularMarketDayHigh": 3.96, "payoutRatio": 0.0, "beta": 1.345, "forwardPE": -2.4444444, "volume": 1141578, "regularMarketVolume": 1141578, "averageVolume": 1864244, "averageVolume10days": 7890550, "averageDailyVolume10Day": 7890550, "bid": 3.95, "ask": 3.96, "bidSize": 11, "askSize": 30, "marketCap": 255664736, "fiftyTwoWeekLow": 0.721, "fiftyTwoWeekHigh": 6.24, "fiftyDayAverage": 1.3934, "twoHundredDayAverage": 2.90745, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 217842816, "profitMargins": 0.0, "floatShares": 36681446, "sharesOutstanding": 64561800, "sharesShort": 3985553, "sharesShortPriorMonth": 4206464, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.0617, "heldPercentInsiders": 0.012259999, "heldPercentInstitutions": 0.83366996, "shortRatio": 8.8, "shortPercentOfFloat": 0.066700004, "impliedSharesOutstanding": 64561800, "bookValue": 0.493, "priceToBook": 8.0324545, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -106716000, "trailingEps": -1.68, "forwardEps": -1.62, "enterpriseToEbitda": -2.08, "52WeekChange": -0.100000024, "SandP52WeekChange": 0.09362543, "quoteType": "EQUITY", "currentPrice": 3.96, "targetHighPrice": 4.0, "targetLowPrice": 4.0, "targetMeanPrice": 4.0, "targetMedianPrice": 4.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 5, "totalCash": 84776000, "totalCashPerShare": 1.313, "ebitda": -104737000, "totalDebt": 46954000, "quickRatio": 1.982, "currentRatio": 2.189, "debtToEquity": 147.663, "returnOnAssets": -0.48452, "returnOnEquity": -1.4168899, "freeCashflow": -56378000, "operatingCashflow": -96523000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "INZY", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1748044718, "regularMarketTime": 1748030401, "exchange": "NMS", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "fiftyDayAverageChange": 2.5666, "fiftyDayAverageChangePercent": 1.8419694, "twoHundredDayAverageChange": 1.0525501, "twoHundredDayAverageChangePercent": 0.3620183, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-07-24", "averageAnalystRating": "3.0 - Hold", "cryptoTradeable": false, "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1864244, "fiftyTwoWeekLowChange": 3.239, "fiftyTwoWeekLowChangePercent": 4.4923716, "fiftyTwoWeekRange": "0.721 - 6.24", "fiftyTwoWeekHighChange": -2.2799997, "fiftyTwoWeekHighChangePercent": -0.36538458, "fiftyTwoWeekChangePercent": -10.000002, "earningsTimestamp": 1747222200, "earningsTimestampStart": 1754310600, "earningsTimestampEnd": 1754656200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.68, "epsForward": -1.62, "epsCurrentYear": -1.24, "priceEpsCurrentYear": -3.1935484, "regularMarketChangePercent": 0.0, "regularMarketPrice": 3.96, "messageBoardId": "finmb_568596329", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1595597400000, "postMarketChangePercent": -0.257576, "postMarketPrice": 3.9498, "postMarketChange": -0.0102, "regularMarketChange": 0.0, "regularMarketDayRange": "3.95 - 3.96", "marketState": "CLOSED", "displayName": "Inozyme Pharma", "trailingPegRatio": null, "__fetch_time": "2025-05-24"}]